Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.16 - $0.42 $87,688 - $230,182
-548,054 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$1.0 - $3.0 $423,054 - $1.27 Million
423,054 Added 338.44%
548,054 $811,000
Q3 2020

Nov 13, 2020

BUY
$0.77 - $1.52 $96,250 - $190,000
125,000 New
125,000 $105,000

About Salarius Pharmaceuticals, Inc.


  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $5.1M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Kepos Capital LP Portfolio

Follow Kepos Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kepos Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Kepos Capital LP with notifications on news.